Dyne Therapeutics
124 hedge funds and large institutions have $957M invested in Dyne Therapeutics in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 40 reducing their positions, and 14 closing their positions.
176% more call options, than puts
Call options by funds: $16M | Put options by funds: $5.78M
79% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 14
78% more capital invested
Capital invested by funds: $537M → $957M (+$420M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
19.06% more ownership
Funds ownership: 98.15% → 117.21% (+19%)
9% more funds holding
Funds holding: 114 → 124 (+10)
8% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$38.4M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$11.6M |
| 3 |
CC
Commodore Capital
New York
|
+$8.79M |
| 4 |
BlackRock
New York
|
+$4.71M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$10.4M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.25M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$3.94M |
| 4 |
AC
Armistice Capital
New York
|
-$3.67M |
| 5 |
Goldman Sachs
New York
|
-$3.39M |
DYN Hedge Fund Activity: Q4 2023 in Review
124 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q4 2023, worth a combined $957M — up 78% from $537M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new DYN positions and 14 closed out — a net gain of 11 holders — while 43 added to existing stakes and 40 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $38.4M. The largest seller was Braidwell, cutting an estimated $10.4M.
- 124 institutional investors held Dyne Therapeutics (DYN) as of Q4 2023, up from 114 in Q3 2023.
- Funds reported $957M of Dyne Therapeutics stock for Q4 2023, up 78% quarter-over-quarter.
- 25 funds opened new Dyne Therapeutics positions in Q4 2023 and 14 closed out, a net change of +11 holders.
- The largest Dyne Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $38.4M added.
- The largest Dyne Therapeutics seller in Q4 2023 was Braidwell, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2023.